Ligand

Beactica Therapeutics' TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, February 14, 2024

STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research's Annual Meeting 2024.

Key Points: 
  • STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research's Annual Meeting 2024.
  • Dr Peter Brandt, Head of Chemistry, will present a poster entitled Degraders of TEAD transcription factors based on interface 3 binders on Sunday April 7, 2024, at 1:30 PM – 5:00 PM.
  • The presentation will include new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands under development by Beactica.
  • Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world.

Beactica Therapeutics' TEAD programme selected for late-breaking research presentation at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, February 14, 2024

STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research's Annual Meeting 2024.

Key Points: 
  • STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD programme has been selected for a late-breaking presentation at the American Association for Cancer Research's Annual Meeting 2024.
  • Dr Peter Brandt, Head of Chemistry, will present a poster entitled Degraders of TEAD transcription factors based on interface 3 binders on Sunday April 7, 2024, at 1:30 PM – 5:00 PM.
  • The presentation will include new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands under development by Beactica.
  • Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world.

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Retrieved on: 
Tuesday, February 6, 2024

The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.

Key Points: 
  • The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.
  • Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg designed the T-FINDER platform to solve this problem.
  • This work provides key insights into the mechanism of anti-tumor T cell responses in these patients and will support ongoing vaccination studies.
  • "Previously, we have been limited in the tools we could use to study class II-presented epitopes such as mutant H3.

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Retrieved on: 
Thursday, February 1, 2024

This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.

Key Points: 
  • This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.
  • Then, a radionuclide held tightly by Perspective’s proprietary chelator attached to an Adma group is administered.
  • The research conducted at Stony Brook University refines the understanding of the potential of the proprietary CB7-Adma pre-targeting platform for image-guided radionuclide therapy for oncology.
  • The technology was first described by Stony Brook University researchers, Jacob L. Houghton, Ph.D. and Vilma I.J.

High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies

Retrieved on: 
Tuesday, January 30, 2024

High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies.

Key Points: 
  • High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies.
  • These will then be biologically validated and biochemically characterized by Institut Curie and the University of Bordeaux respectively.
  • This collaborative approach reflects the shared commitment of Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux to explore innovative approaches to the development of more targeted and effective cancer therapies.
  • We are delighted and honored to be working with the Institut Curie & the University of Bordeaux along these lines."

Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024: Insights On 10 Current & Potential Proprietary Platforms, Company, Indication & Phase for 15 Drugs, and 14 Companies - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 1, 2024

The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024 Report Finding & Highlights:
    Insight On Current & Potential DLL3 Targeted Therapies Proprietary Platforms: > 10 Platform
    DLL3 Targeted Drugs Clinical Trials Insight By Company, Indication & Phase: > 15 Drugs
    Insight On Companies Involved In R&D Of DLL3 Targeted Therapies: 14 Companies
    In recent years, the discovery of Delta Like Ligand 3 (DLL3) as a therapeutic cancer target has emerged as key defining moment in the targeted therapy landscape.
  • Stemcentrx, now a subsidiary of AbbVie, led the development of Rovalpituzumab tesirine (Rova-T), which was a pioneering endeavor in the field of DLL3 targeted therapies.
  • The dynamic evolution of DLL3 targeted therapies is characterized by a wide range of candidates in clinical trials, extending far beyond Rovalpituzumab conjugates.

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Retrieved on: 
Thursday, January 18, 2024

VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades.

Key Points: 
  • VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades.
  • Inhibitory signaling is induced when VSTM-1 binds to ligands such as cathelicidin and S100 proteins.
  • NextCure developed an agonist monoclonal antibody (mAb) against VSTM-1 to modulate hyperinflammatory conditions, restore homeostasis and prevent disease.
  • The data were presented in a poster presentation at the 2024 Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy:

Enigma Biomedical Group - USA Signs License Agreement with AbbVie for Novel 4R Tau PET Imaging Biomarkers

Retrieved on: 
Thursday, January 18, 2024

Enigma Biomedical Group - USA (EBG-USA) today announced it has signed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie’s next-generation F18 PET imaging biomarkers to assess the presence of four-repeat (4R) tau protein in patients with suspected neurodegenerative disease.

Key Points: 
  • Enigma Biomedical Group - USA (EBG-USA) today announced it has signed an exclusive license and option agreement with AbbVie for the development and potential commercialization of AbbVie’s next-generation F18 PET imaging biomarkers to assess the presence of four-repeat (4R) tau protein in patients with suspected neurodegenerative disease.
  • The 4R tau PET imaging biomarkers hold great promise as important new tools in advancing the understanding of neurodegenerative diseases linked to misfolded 4R tau protein, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).
  • The agreement permits EBG-USA to evaluate AbbVie’s next-generation F18 PET imaging biomarkers.
  • If the evaluations are favorable, EBG-USA has the option to negotiate an exclusive license agreement with AbbVie for the PET ligands.

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

Retrieved on: 
Friday, January 5, 2024

The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world.

Key Points: 
  • The 70,000-square foot site, the company’s second US location, is designed specifically for RLT manufacturing and is now the largest and most advanced Novartis facility of its kind in the world.
  • The Indianapolis site represents the next phase of RLT manufacturing growth as this new addition brings substantial supply increases for the foreseeable future.
  • “The intricate process of providing RLTs to patients within hours of production requires precision manufacturing expertise to bring these medicines to individuals who critically need them,” said Steffen Lang, President, Operations, Novartis.
  • Novartis is committed to expanding the radioligand therapy platform to shape the future of RLT as a treatment class.

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024

WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings, has issued a Letter to Shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.

Key Points: 
  • WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings, has issued a Letter to Shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.
  • Our strategy is to leverage these innovative and complementary platforms to develop powerful, personalized cell-based treatments to improve outcomes for patients with cancer.
  • As we look to 2024, we see enormous potential to advance our pipeline and achieve meaningful growth milestones.
  • On behalf of the entire Coeptis team, I wish you all a happy and healthy 2024.